ArticleThe Journal of clinical investigation2000
Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 110 citations in OpenAlex.
- Ocular immune homeostasis-mechanisms of precise regulation through coordination of the eye, visual system and beyond: a narrative review.Annals of eye science · 2026Article
- Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.Frontiers in immunology · 2019Review
- Review
- Tolerance Induction in Relation to the Eye.Frontiers in immunology · 2018Review
- In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.Advanced drug delivery reviews · 2017Review
- From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Frontiers in immunology · 2017Review
- Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.Cellular immunology · 2016Article
- Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms.Frontiers in immunology · 2016Review
- Cell therapy to induce allograft tolerance: time to switch to plan B?Frontiers in immunology · 2015Review
- Inhibitors - cellular aspects and novel approaches for tolerance.Haemophilia : the official journal of the World Federation of Hemophilia · 2014Review
- Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.Journal of leukocyte biology · 2013Article
- Non-myeloablative transplantation of bone marrow expressing self-antigen establishes peripheral tolerance and completely prevents autoimmunity in mice.Gene therapy · 2012Article
- Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE.Clinical immunology (Orlando, Fla.) · 2011Article
- IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.European journal of immunology · 2011Article
- High Efficiency Ex Vivo Gene Transfer to Primary Murine B Cells Using Plasmid or Viral Vectors.Journal of genetic syndromes & gene therapy · 2011Article
- Understanding autoimmune uveitis through animal models. The Friedenwald Lecture.Investigative ophthalmology & visual science · 2011Article
- Anti-CD3 antibody ameliorates experimental autoimmune uveitis by inducing both IL-10 and TGF-β dependent regulatory T cells.Clinical immunology (Orlando, Fla.) · 2011Article
- B-Cell Gene Therapy for Tolerance Induction: Host but Not Donor B-Cell Derived IL-10 is Necessary for Tolerance.Frontiers in microbiology · 2011Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Immunoglobulins can serve as tolerogenic carriers for antigens, and B cells can function as tolerogenic antigen-presenting cells. We used this principle to design a strategy for gene therapy of experimental autoimmune uveitis, a cell-mediated autoimmune disease model for human uveitis induced with the uveitogenic interphotoreceptor retinoid-binding protein (IRBP). A retroviral vector was constructed containing a major uveitogenic IRBP epitope in frame with mouse IgG1 heavy chain. This construct was used to transduce peripheral B cells, which were infused into syngeneic recipients. A single infusion of transduced cells, 10 days before uveitogenic challenge, protected mice from clinical disease induced with the epitope or with the native IRBP protein. Protected mice had reduced antigen-specific responses, but showed no evidence for a classic Th1/Th2 response shift or for generalized anergy. Protection was not transferable, arguing against a mechanism dependent on regulatory cells. Importantly, the treatment was protective when initiated 7 days after uveitogenic immunization or concurrently with adoptive transfer of primed uveitogenic T cells. We suggest that this form of gene therapy can induce epitope-specific protection not only in naive, but also in already primed recipients, thus providing a protocol for treatment of established autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.